Oct 21 (Reuters) - Elevai Labs Inc :
* ELEVAI BIOSCIENCES, A SUBSIDIARY OF ELEVAI LABS INC., HIGHLIGHTS PAST POSITIVE PRECLINICAL DATA SHOWING POTENTIAL OF EL-32, A DUAL MYOSTATIN & ACTIVIN-A BLOCKER, FOR THE TREATMENT OF OBESITY
* ELEVAI: EL-32 PRECLINICAL RESULTS SHOWED STATISTICALLY SIGNIFICANT INCREASES IN GRIP STRENGTH, MOTOR FUNCTION & BODY COMPOSITION IN AGED MOUSE MODEL
* ELEVAI: TO CONDUCT ADDITIONAL ANIMAL STUDIES TO ADVANCE EL-32 TOWARDS IND APPLICATION
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.